Corona Virus Covid 19

Tourists’ inflow picks up in Himachal Pradesh with relaxations in COVID restrictions
Jul 6, 2021



135K subscribers

Himachal Pradesh has started witnessing an inflow of tourists following relaxation in COVID restrictions by the state government. In less than a month starting from June, there has been traffic of around 6-7 lakh tourists in the Himalayan state. Tourists have started thronging to the destinations like Shimla, Manali, Dharamshala, Dalhousie, Narkanda and other parts of the state. Speaking to ANI, Himachal Pradesh Tourism Department Director Amit Kashyap said, “This year till May 31, we received only 13 lakh tourists. But now in June after the restrictions have been relaxed, we have received 6 to 7 Lakh tourists within this period. We have developed the SOPs for the tourists. Meetings were held with the hotel operators, tourism and travel associations. Tourism is a major source of income for the state's economy and we are trying to revive this business. It is being ensured that the protocol is being followed,” Kashyap added.
Covaxin to get WHO nod soon? Chief scientist says Covid-19 vaccine trial data 'looks good'

WHO chief scientist Soumya Swaminathan said even as Covaxin's efficacy against the Delta variant of Covid-19 is a bit low the overall efficacy of the vaccine is "quite high."
By | Written by Joydeep Bose | Edited by Avik Roy
PUBLISHED ON JUL 09, 2021 08:08 AM IST
In what potentially comes as a piece of good news for Hyderabad-based vaccine manufacturer Bharat Biotech, the World Health Organization (WHO) has indicated that it might just provide its much-awaited approval to Covaxin, the company's indigenous jab against the coronavirus disease (Covid-19).

Soumya Swaminathan, the chief scientist at WHO, told a Mumbai-based news organisation that the final phase trial data for Covaxin “looks good” and meets the safety profile of the international public health agency so far.

The pre-submission meeting between Bharat Biotech and WHO was held on June 23, Swaminathan told CNBC TV-18 in an interview, adding that the data packet is currently being assembled. She noted that although Covaxin's efficacy against the Delta variant of Covid-19 is a bit low, it is still not bad, while the overall efficacy is "quite high."
Bharat Biotech finally made public its findings from the Phase-3 efficacy analysis of Covaxin last Saturday, where it claimed an overall efficacy of 77.8% against symptomatic Covid-19 patients. The pre-print data from "India's largest efficacy trial" showed that Covaxin demonstrates 93.4% effectiveness against severe symptomatic Covid-19 cases. On the other hand, Covaxin provides 65.2% protection against the B.1.617.2 (Delta) strain, currently the most predominant Covid-19 variant in India, it said.

Kempty Fall at Mussoorie. (File photo)

The World Health Organization keeps a close watch on all the vaccines which are on the pipeline for emergency listing, Swaminathan said, adding that the agency is awaiting more data for a final say on the matter.
Speaking on the Covid-19 situation in India, the WHO chief scientist said that the government should focus on primary immunisation of at least 60-70% of its population. The focus should not be on booster shots but on broadening the scope of primary vaccination, she said. Only after a sizeable population has been vaccinated can India draw inspiration from countries like the United Kingdom, which have moved on to focusing on booster doses.
Most of the world, except some districts in the United States, has recently seen a spurt in Covid-19 cases while there has been no reduction in the death toll, Swaminathan noted.

Notably, Bharat Biotech's Covid-19 vaccine Covaxin has till now not found a place in the World Health Organization's emergency-use listing (EUL) of vaccines. The lack of endorsement from WHO has been hampering travel plans for individuals as many countries are only accepting vaccines approved by the public health body.
Covaxin is one of the three vaccines which are currently being used in India for inoculation of people against the coronavirus disease (Covid-19). The vaccine is developed by Hyderabad-based pharmaceutical company Bharat Biotech in association with the Indian Council of Medical Research (ICMR).
Serum Institute of India's Covishield and Russia's Sputnik V are the other two vaccines that have been administered to Indian citizens so far. Moderna's Covid-19 messenger RNA (mRNA) vaccine is expected to reach India this week, reported news agencies. However, discussions are still going on over indemnity waivers.

Covaxin to get WHO nod soon? Chief scientist says Covid-19 vaccine trial data 'looks good'
Biden warns Americans about coronavirus Delta variant
Jul 7, 2021



1.11M subscribers

President Joe Biden encouraged Americans who have not yet been vaccinated against COVID-19 to get their shots to protect themselves from the widely spreading, highly contagious Delta variant of the coronavirus.
Why so many Covid-19 variants are showing up now
Jun 16, 2021



9.76M subscribers

And what that tells us about the pandemic.
Gravitas: 2 new 'super infective' variants identified in India
Jun 8, 2021



3.01M subscribers

India's second wave is slowing down but hurdles remain.2 new 'super infective' variants have been identified. They can spread faster & cause weight loss. Will vaccines work on them? WION's Palki Sharma gets you a report.
Gravitas | Delta Plus variant: The new worry for the world
Jun 22, 2021



3.01M subscribers

As the world struggles with the Delta variant, the virus has mutated again. At least 9 countries have now detected the "Delta plus" variant, with India reporting around 30 cases of the new mutation. Palki Sharma tells you why this variant has sparked concerns.
Gravitas: Indonesia suffers as Chinese Vaccines fail
Jun 28, 2021



3.01M subscribers

20 doctors have died in #Indonesia despite being fully vaccinated with Sinovac. Around 90% of the country's doctor took the Chinese shot, they're now worried with the rising infections among healthcare workers. Have Chinese vaccines failed?
After Delta, Now Lambda Variant of Covid-19 Sparks Fear: Should India Be Worried?
Jul 7, 2021



776K subscribers

Even as the Delta variant continues to drive fresh Covid cases, a new variant called Lambda is seen as an emerging threat. The variant with the formal scientific name of C.37 was designated the Lambda variant by WHO on June 14. The variant has been around as early as August 2020. The strain accounts for almost 80% of the infections in Peru, where it is believed to have originated. #LambdaVarient #Coronavirus